Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Gallium in cancer treatment.
View on PubMed
Reviews of Physiology, Biochemistry and Pharmacology
  • B. Keppler
  • Chemistry
    Reviews of Physiology, Biochemistry and…
  • 2003
Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field of research. This article reviews the…
View on Springer
Antitumour metal compounds: more than theme and variations.
TLDR
Strategies opening up new avenues are increasingly being sought using complexes of metals other than platinum such as ruthenium or gallium, based on the chemical differences between these metals, the spectrum of molecular mechanisms of action and potential indications can be broadened substantially.
View on PubMed
Tumour-inhibiting platinum complexes--state of the art and future perspectives.
TLDR
The current preclinical and clinical status is reviewed, including a discussion of the molecular basis for the activity of the parent drug cisplatin and platinum drugs of the second and third generation, in particular their interaction with DNA.
View on PubMed
KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
TLDR
The experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction.
View on Wiley
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.
TLDR
This article reviews the recent development of preclinical platinum complexes with interesting in vitro and in vivo tumor inhibiting properties and focuses also on innovative synthetic strategies leading to novel classes of platinum complexes.
View on PubMed
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
TLDR
Taken together, KP1019 and NKP-1339 are promising drug candidates, and especially the very limited side effects observed so far in clinical phase I trials seem to be a major advantage of this class of ruthenium drugs as compared to other chemotherapeutics and targeted anticancer compounds.
View PDF
Relevance of peat-draining rivers for the riverine input of dissolved iron into the ocean.
View on PubMed
KP1019, A New Redox-Active Anticancer Agent — Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
View via Publisher
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License